Selected research
Industry Research
Chronic Idiopathic Constipation Drugs Industry Research Report 2026
Market perspective
The global Chronic Idiopathic Constipation Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Chronic Idiopathic Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Chronic Idiopathic Constipation Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Chronic Idiopathic Constipation Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Chronic Idiopathic Constipation Drugs include Sanofi, Merck, Eli Lilly, Pfizer, Glaxosmithkline, Bayer AG, Theravance Biopharma Inc, Synergy Pharmaceuticals and Sucampo Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Chronic Idiopathic Constipation Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Chronic Idiopathic Constipation Drugs Market by Company
Sanofi
Merck
Eli Lilly
Pfizer
Glaxosmithkline
Bayer AG
Theravance Biopharma Inc
Synergy Pharmaceuticals
Sucampo Pharmaceuticals Inc
Salix Pharmaceuticals Ltd
Roche Holding AG
Progenics Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Ferring International Center S.A
Daiichi Sankyo
Cosmo Pharmaceuticals SA
Chugai Pharmaceutical
Bausch Health
Allergens
Chronic Idiopathic Constipation Drugs Segment by Type
Linaclotide
Lubiprostone
Others
Chronic Idiopathic Constipation Drugs Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Chronic Idiopathic Constipation Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Idiopathic Constipation Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chronic Idiopathic Constipation Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Idiopathic Constipation Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Chronic Idiopathic Constipation Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Chronic Idiopathic Constipation Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Chronic Idiopathic Constipation Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Chronic Idiopathic Constipation Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Chronic Idiopathic Constipation Drugs Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Chronic Idiopathic Constipation Drugs Revenue of Manufacturers (2021-2026)
Table 9. Global Chronic Idiopathic Constipation Drugs Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Chronic Idiopathic Constipation Drugs Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Chronic Idiopathic Constipation Drugs Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Chronic Idiopathic Constipation Drugs, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Chronic Idiopathic Constipation Drugs, Product Type & Application
Table 14. Global Chronic Idiopathic Constipation Drugs Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Chronic Idiopathic Constipation Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Sanofi Company Information
Table 19. Sanofi Business Overview
Table 20. Sanofi Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Sanofi Chronic Idiopathic Constipation Drugs Product Portfolio
Table 22. Sanofi Recent Developments
Table 23. Merck Company Information
Table 24. Merck Business Overview
Table 25. Merck Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Merck Chronic Idiopathic Constipation Drugs Product Portfolio
Table 27. Merck Recent Developments
Table 28. Eli Lilly Company Information
Table 29. Eli Lilly Business Overview
Table 30. Eli Lilly Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Eli Lilly Chronic Idiopathic Constipation Drugs Product Portfolio
Table 32. Eli Lilly Recent Developments
Table 33. Pfizer Company Information
Table 34. Pfizer Business Overview
Table 35. Pfizer Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Pfizer Chronic Idiopathic Constipation Drugs Product Portfolio
Table 37. Pfizer Recent Developments
Table 38. Glaxosmithkline Company Information
Table 39. Glaxosmithkline Business Overview
Table 40. Glaxosmithkline Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Glaxosmithkline Chronic Idiopathic Constipation Drugs Product Portfolio
Table 42. Glaxosmithkline Recent Developments
Table 43. Bayer AG Company Information
Table 44. Bayer AG Business Overview
Table 45. Bayer AG Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Bayer AG Chronic Idiopathic Constipation Drugs Product Portfolio
Table 47. Bayer AG Recent Developments
Table 48. Theravance Biopharma Inc Company Information
Table 49. Theravance Biopharma Inc Business Overview
Table 50. Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Product Portfolio
Table 52. Theravance Biopharma Inc Recent Developments
Table 53. Synergy Pharmaceuticals Company Information
Table 54. Synergy Pharmaceuticals Business Overview
Table 55. Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Product Portfolio
Table 57. Synergy Pharmaceuticals Recent Developments
Table 58. Sucampo Pharmaceuticals Inc Company Information
Table 59. Sucampo Pharmaceuticals Inc Business Overview
Table 60. Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
Table 62. Sucampo Pharmaceuticals Inc Recent Developments
Table 63. Salix Pharmaceuticals Ltd Company Information
Table 64. Salix Pharmaceuticals Ltd Business Overview
Table 65. Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Product Portfolio
Table 67. Salix Pharmaceuticals Ltd Recent Developments
Table 68. Roche Holding AG Company Information
Table 69. Roche Holding AG Business Overview
Table 70. Roche Holding AG Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Roche Holding AG Chronic Idiopathic Constipation Drugs Product Portfolio
Table 72. Roche Holding AG Recent Developments
Table 73. Progenics Pharmaceuticals Inc Company Information
Table 74. Progenics Pharmaceuticals Inc Business Overview
Table 75. Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
Table 77. Progenics Pharmaceuticals Inc Recent Developments
Table 78. Ironwood Pharmaceuticals Inc Company Information
Table 79. Ironwood Pharmaceuticals Inc Business Overview
Table 80. Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
Table 82. Ironwood Pharmaceuticals Inc Recent Developments
Table 83. Ferring International Center S.A Company Information
Table 84. Ferring International Center S.A Business Overview
Table 85. Ferring International Center S.A Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Ferring International Center S.A Chronic Idiopathic Constipation Drugs Product Portfolio
Table 87. Ferring International Center S.A Recent Developments
Table 88. Daiichi Sankyo Company Information
Table 89. Daiichi Sankyo Business Overview
Table 90. Daiichi Sankyo Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Daiichi Sankyo Chronic Idiopathic Constipation Drugs Product Portfolio
Table 92. Daiichi Sankyo Recent Developments
Table 93. Cosmo Pharmaceuticals SA Company Information
Table 94. Cosmo Pharmaceuticals SA Business Overview
Table 95. Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Product Portfolio
Table 97. Cosmo Pharmaceuticals SA Recent Developments
Table 98. Chugai Pharmaceutical Company Information
Table 99. Chugai Pharmaceutical Business Overview
Table 100. Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Product Portfolio
Table 102. Chugai Pharmaceutical Recent Developments
Table 103. Bausch Health Company Information
Table 104. Bausch Health Business Overview
Table 105. Bausch Health Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Bausch Health Chronic Idiopathic Constipation Drugs Product Portfolio
Table 107. Bausch Health Recent Developments
Table 108. Allergens Company Information
Table 109. Allergens Business Overview
Table 110. Allergens Chronic Idiopathic Constipation Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Allergens Chronic Idiopathic Constipation Drugs Product Portfolio
Table 112. Allergens Recent Developments
Table 113. Global Chronic Idiopathic Constipation Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 114. Global Chronic Idiopathic Constipation Drugs Sales by Region (2021-2026) & (K Units)
Table 115. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Region (2021-2026)
Table 116. Global Chronic Idiopathic Constipation Drugs Sales by Region (2027-2032) & (K Units)
Table 117. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Region (2027-2032)
Table 118. Global Chronic Idiopathic Constipation Drugs Revenue by Region (2021-2026) & (US$ Million)
Table 119. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Region (2021-2026)
Table 120. Global Chronic Idiopathic Constipation Drugs Revenue by Region (2027-2032) & (US$ Million)
Table 121. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Region (2027-2032)
Table 122. North America Chronic Idiopathic Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 123. North America Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 124. North America Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 125. North America Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 126. North America Chronic Idiopathic Constipation Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 127. Europe Chronic Idiopathic Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 128. Europe Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 129. Europe Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 130. Europe Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 131. Europe Chronic Idiopathic Constipation Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 132. Asia Pacific Chronic Idiopathic Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 133. Asia Pacific Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 134. Asia Pacific Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 135. Asia Pacific Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 136. Asia Pacific Chronic Idiopathic Constipation Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 137. South America Chronic Idiopathic Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 138. South America Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 139. South America Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 140. South America Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 141. South America Chronic Idiopathic Constipation Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 142. Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 143. Middle East and Africa Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 144. Middle East and Africa Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 145. Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 146. Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 147. Global Chronic Idiopathic Constipation Drugs Sales by Type (2021-2026) & (K Units)
Table 148. Global Chronic Idiopathic Constipation Drugs Sales by Type (2027-2032) & (K Units)
Table 149. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Type (2021-2026)
Table 150. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Type (2027-2032)
Table 151. Global Chronic Idiopathic Constipation Drugs Revenue by Type (2021-2026) & (US$ Million)
Table 152. Global Chronic Idiopathic Constipation Drugs Revenue by Type (2027-2032) & (US$ Million)
Table 153. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Type (2021-2026)
Table 154. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Type (2027-2032)
Table 155. Global Chronic Idiopathic Constipation Drugs Price by Type (2021-2026) & (US$/Unit)
Table 156. Global Chronic Idiopathic Constipation Drugs Price by Type (2027-2032) & (US$/Unit)
Table 157. Global Chronic Idiopathic Constipation Drugs Sales by Application (2021-2026) & (K Units)
Table 158. Global Chronic Idiopathic Constipation Drugs Sales by Application (2027-2032) & (K Units)
Table 159. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Application (2021-2026)
Table 160. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Application (2027-2032)
Table 161. Global Chronic Idiopathic Constipation Drugs Revenue by Application (2021-2026) & (US$ Million)
Table 162. Global Chronic Idiopathic Constipation Drugs Revenue by Application (2027-2032) & (US$ Million)
Table 163. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Application (2021-2026)
Table 164. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Application (2027-2032)
Table 165. Global Chronic Idiopathic Constipation Drugs Price by Application (2021-2026) & (US$/Unit)
Table 166. Global Chronic Idiopathic Constipation Drugs Price by Application (2027-2032) & (US$/Unit)
Table 167. Key Raw Materials
Table 168. Raw Materials Key Suppliers
Table 169. Chronic Idiopathic Constipation Drugs Distributors List
Table 170. Chronic Idiopathic Constipation Drugs Customers List
Table 171. Chronic Idiopathic Constipation Drugs Industry Trends
Table 172. Chronic Idiopathic Constipation Drugs Industry Drivers
Table 173. Chronic Idiopathic Constipation Drugs Industry Restraints
Table 174. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Chronic Idiopathic Constipation Drugs Product Image
Figure 5. Global Chronic Idiopathic Constipation Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Chronic Idiopathic Constipation Drugs Market Size (2021-2032) & (US$ Million)
Figure 7. Global Chronic Idiopathic Constipation Drugs Sales (2021-2032) & (K Units)
Figure 8. Global Chronic Idiopathic Constipation Drugs Average Price (US$/Unit) & (2021-2032)
Figure 9. Linaclotide Product Image
Figure 10. Lubiprostone Product Image
Figure 11. Others Product Image
Figure 12. Retail Pharmacies Product Image
Figure 13. Online Pharmacies Product Image
Figure 14. Hospital Pharmacies Product Image
Figure 15. Global Chronic Idiopathic Constipation Drugs Revenue Share by Manufacturers in 2025
Figure 16. Global Manufacturers of Chronic Idiopathic Constipation Drugs, Manufacturing Sites & Headquarters
Figure 17. Global Top 5 and 10 Chronic Idiopathic Constipation Drugs Players Market Share by Revenue in 2025
Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 19. Global Chronic Idiopathic Constipation Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 20. Global Chronic Idiopathic Constipation Drugs Sales by Region in 2025
Figure 21. Global Chronic Idiopathic Constipation Drugs Revenue by Region in 2025
Figure 22. North America Chronic Idiopathic Constipation Drugs Market Size by Country in 2025
Figure 23. North America Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 24. North America Chronic Idiopathic Constipation Drugs Revenue Market Share by Country (2021-2032)
Figure 25. United States Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 26. Canada Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 27. Europe Chronic Idiopathic Constipation Drugs Market Size by Country in 2025
Figure 28. Europe Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 29. Europe Chronic Idiopathic Constipation Drugs Revenue Market Share by Country (2021-2032)
Figure 30. Germany Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 31. France Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 32. U.K. Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. Italy Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. Netherlands Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Nordic Countries Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Asia Pacific Chronic Idiopathic Constipation Drugs Market Size by Country in 2025
Figure 37. Asia Pacific Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 38. Asia Pacific Chronic Idiopathic Constipation Drugs Revenue Market Share by Country (2021-2032)
Figure 39. China Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Japan Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. South Korea Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. India Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Australia Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. China Taiwan Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. Southeast Asia Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Southeast Asia Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. South America Chronic Idiopathic Constipation Drugs Market Size by Country in 2025
Figure 48. South America Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 49. South America Chronic Idiopathic Constipation Drugs Revenue Market Share by Country (2021-2032)
Figure 50. Mexico Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Brazil Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Argentina Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. Colombia Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. Middle East and Africa Chronic Idiopathic Constipation Drugs Market Size by Country in 2025
Figure 55. Middle East and Africa Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 56. Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue Market Share by Country (2021-2032)
Figure 57. Turkey Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Saudi Arabia Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. UAE Chronic Idiopathic Constipation Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Type (2021-2032)
Figure 61. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Type (2021-2032)
Figure 62. Global Chronic Idiopathic Constipation Drugs Price (US$/Unit) by Type (2021-2032)
Figure 63. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Application (2021-2032)
Figure 64. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Application (2021-2032)
Figure 65. Global Chronic Idiopathic Constipation Drugs Price (US$/Unit) by Application (2021-2032)
Figure 66. Chronic Idiopathic Constipation Drugs Value Chain
Figure 67. Chronic Idiopathic Constipation Drugs Production Mode & Process
Figure 68. Direct Comparison with Distribution Share
Figure 69. Distributors Profiles
Figure 70. Chronic Idiopathic Constipation Drugs Industry Opportunities and Challenges
Scope & coverage.
Types
- Linaclotide
- Lubiprostone
- Others
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Sanofi
- Merck
- Eli Lilly
- Pfizer
- Glaxosmithkline
- Bayer AG
- Theravance Biopharma Inc
- Synergy Pharmaceuticals
- Sucampo Pharmaceuticals Inc
- Salix Pharmaceuticals Ltd
- Roche Holding AG
- Progenics Pharmaceuticals Inc
- Ironwood Pharmaceuticals Inc
- Ferring International Center S.A
- Daiichi Sankyo
- Cosmo Pharmaceuticals SA
- Chugai Pharmaceutical
- Bausch Health
- Allergens
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Chronic Idiopathic Constipation Drugs Market Size (2021-2032)
- 2.2.2 Global Chronic Idiopathic Constipation Drugs Sales (2021-2032)
- 2.2.3 Global Chronic Idiopathic Constipation Drugs Market Average Price (2021-2032)
- 2.3 Chronic Idiopathic Constipation Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Linaclotide
- 2.3.3 Lubiprostone
- 2.3.4 Others
- 2.4 Chronic Idiopathic Constipation Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Hospital Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Chronic Idiopathic Constipation Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Chronic Idiopathic Constipation Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Chronic Idiopathic Constipation Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Chronic Idiopathic Constipation Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Chronic Idiopathic Constipation Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Chronic Idiopathic Constipation Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Chronic Idiopathic Constipation Drugs, Product Type & Application
- 3.8 Global Manufacturers of Chronic Idiopathic Constipation Drugs, Established Date
- 3.9 Global Chronic Idiopathic Constipation Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Eli Lilly
- 4.3.1 Eli Lilly Company Information
- 4.3.2 Eli Lilly Business Overview
- 4.3.3 Eli Lilly Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.3.5 Eli Lilly Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Glaxosmithkline
- 4.5.1 Glaxosmithkline Company Information
- 4.5.2 Glaxosmithkline Business Overview
- 4.5.3 Glaxosmithkline Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Glaxosmithkline Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.5.5 Glaxosmithkline Recent Developments
- 4.6 Bayer AG
- 4.6.1 Bayer AG Company Information
- 4.6.2 Bayer AG Business Overview
- 4.6.3 Bayer AG Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer AG Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.6.5 Bayer AG Recent Developments
- 4.7 Theravance Biopharma Inc
- 4.7.1 Theravance Biopharma Inc Company Information
- 4.7.2 Theravance Biopharma Inc Business Overview
- 4.7.3 Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.7.5 Theravance Biopharma Inc Recent Developments
- 4.8 Synergy Pharmaceuticals
- 4.8.1 Synergy Pharmaceuticals Company Information
- 4.8.2 Synergy Pharmaceuticals Business Overview
- 4.8.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.8.5 Synergy Pharmaceuticals Recent Developments
- 4.9 Sucampo Pharmaceuticals Inc
- 4.9.1 Sucampo Pharmaceuticals Inc Company Information
- 4.9.2 Sucampo Pharmaceuticals Inc Business Overview
- 4.9.3 Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.9.5 Sucampo Pharmaceuticals Inc Recent Developments
- 4.10 Salix Pharmaceuticals Ltd
- 4.10.1 Salix Pharmaceuticals Ltd Company Information
- 4.10.2 Salix Pharmaceuticals Ltd Business Overview
- 4.10.3 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.10.5 Salix Pharmaceuticals Ltd Recent Developments
- 4.11 Roche Holding AG
- 4.11.1 Roche Holding AG Company Information
- 4.11.2 Roche Holding AG Business Overview
- 4.11.3 Roche Holding AG Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Roche Holding AG Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.11.5 Roche Holding AG Recent Developments
- 4.12 Progenics Pharmaceuticals Inc
- 4.12.1 Progenics Pharmaceuticals Inc Company Information
- 4.12.2 Progenics Pharmaceuticals Inc Business Overview
- 4.12.3 Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.12.5 Progenics Pharmaceuticals Inc Recent Developments
- 4.13 Ironwood Pharmaceuticals Inc
- 4.13.1 Ironwood Pharmaceuticals Inc Company Information
- 4.13.2 Ironwood Pharmaceuticals Inc Business Overview
- 4.13.3 Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.13.5 Ironwood Pharmaceuticals Inc Recent Developments
- 4.14 Ferring International Center S.A
- 4.14.1 Ferring International Center S.A Company Information
- 4.14.2 Ferring International Center S.A Business Overview
- 4.14.3 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.14.5 Ferring International Center S.A Recent Developments
- 4.15 Daiichi Sankyo
- 4.15.1 Daiichi Sankyo Company Information
- 4.15.2 Daiichi Sankyo Business Overview
- 4.15.3 Daiichi Sankyo Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Daiichi Sankyo Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.15.5 Daiichi Sankyo Recent Developments
- 4.16 Cosmo Pharmaceuticals SA
- 4.16.1 Cosmo Pharmaceuticals SA Company Information
- 4.16.2 Cosmo Pharmaceuticals SA Business Overview
- 4.16.3 Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.16.5 Cosmo Pharmaceuticals SA Recent Developments
- 4.17 Chugai Pharmaceutical
- 4.17.1 Chugai Pharmaceutical Company Information
- 4.17.2 Chugai Pharmaceutical Business Overview
- 4.17.3 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.17.5 Chugai Pharmaceutical Recent Developments
- 4.18 Bausch Health
- 4.18.1 Bausch Health Company Information
- 4.18.2 Bausch Health Business Overview
- 4.18.3 Bausch Health Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Bausch Health Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.18.5 Bausch Health Recent Developments
- 4.19 Allergens
- 4.19.1 Allergens Company Information
- 4.19.2 Allergens Business Overview
- 4.19.3 Allergens Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Allergens Chronic Idiopathic Constipation Drugs Product Portfolio
- 4.19.5 Allergens Recent Developments
5 Global Chronic Idiopathic Constipation Drugs Market Scenario by Region
- 5.1 Global Chronic Idiopathic Constipation Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Chronic Idiopathic Constipation Drugs Sales by Region: 2021-2032
- 5.2.1 Global Chronic Idiopathic Constipation Drugs Sales by Region: 2021-2026
- 5.2.2 Global Chronic Idiopathic Constipation Drugs Sales by Region: 2027-2032
- 5.3 Global Chronic Idiopathic Constipation Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Chronic Idiopathic Constipation Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Chronic Idiopathic Constipation Drugs Revenue by Region: 2027-2032
- 5.4 North America Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country
- 5.4.1 North America Chronic Idiopathic Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 5.4.3 North America Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country
- 5.5.1 Europe Chronic Idiopathic Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Chronic Idiopathic Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country
- 5.7.1 South America Chronic Idiopathic Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 5.7.3 South America Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Chronic Idiopathic Constipation Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Chronic Idiopathic Constipation Drugs Sales by Type (2021-2032)
- 6.1.1 Global Chronic Idiopathic Constipation Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Chronic Idiopathic Constipation Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Chronic Idiopathic Constipation Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Chronic Idiopathic Constipation Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Chronic Idiopathic Constipation Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Chronic Idiopathic Constipation Drugs Sales by Application (2021-2032)
- 7.1.1 Global Chronic Idiopathic Constipation Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Chronic Idiopathic Constipation Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Chronic Idiopathic Constipation Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Chronic Idiopathic Constipation Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Chronic Idiopathic Constipation Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Chronic Idiopathic Constipation Drugs Value Chain Analysis
- 8.1.1 Chronic Idiopathic Constipation Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Chronic Idiopathic Constipation Drugs Production Mode & Process
- 8.2 Chronic Idiopathic Constipation Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Chronic Idiopathic Constipation Drugs Distributors
- 8.2.3 Chronic Idiopathic Constipation Drugs Customers
9 Global Chronic Idiopathic Constipation Drugs Analyzing Market Dynamics
- 9.1 Chronic Idiopathic Constipation Drugs Industry Trends
- 9.2 Chronic Idiopathic Constipation Drugs Industry Drivers
- 9.3 Chronic Idiopathic Constipation Drugs Industry Opportunities and Challenges
- 9.4 Chronic Idiopathic Constipation Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst